Accelerate commercial success with a large, existing user base in the US and globally.1
Guardant Health is uniquely positioned to identify appropriate patients for your therapy.
First FDA-approved comprehensive liquid biopsy with broad Medicare coverage2,3
#1
liquid biopsy market share across tumor types. #1 rated field team. #1 share of voice.4
12k
ordering oncologist user base
>300m
covered lives and counting
Relentless focus to increase access to testing internationally.
When bringing new therapeutics to patients globally, we understand that access to NGS testing can significantly vary by country and region.
Global access to our liquid biopsy tests is one of our top priorities. That’s why we’re partnering with labs and world-renowned cancer centers around the world to ensure that we can bring liquid biopsy to new markets while maintaining our high-quality and performance standards.
Expanding global footprint and maintaining high Guardant Health quality standards.
← Swipe to reveal full chart →
Expand your clinical trials to China.
Through our partnership with Adicon Labs, we can support local testing in China for the development of new therapies. Adicon has an integrated network of laboratories. It's one of the top 3 independent clinical laboratories (ICL) in China.
With this relationship, biopharma companies can expand patient screening and recruitment for their clinical programs to China using Guardant360. To learn more about our analytical validation data, connect with our BioPharma team.
Guardant360 CDx has MLHW approval and is reimbursed under the National Health Insurance system in Japan.
Guardant360 CDx has a growing CDx pipeline in Japan, with plans for in-country testing availability at the CAP-accredited Japan iPark Lab.
Partnering with world-renowned cancer centers in Europe, enabling access to Guardant360.
Our partnership model provides access to in-country testing and is helping to accelerate testing adoption and reimbursement in these key regions. Our first 2 partnerships are with Vall d’Hebron Institute of Oncology (VHIO) in Spain and the Royal Marsden NHS Foundation Trust in the UK.
Partnering with leading organizations in precision oncology around the globe.
Featured Partnerships
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response.
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer.
Guardant Health and Vall d’Hebron Institute of Oncology announce partnership to establish first Guardant-based liquid biopsy testing service in Europe.
CAP, College of American Pathologists-accredited.
References: 1. Data on file. Guardant Infinity. Guardant Health, Inc. Redwood City, CA. 2. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023. 3. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed October 24, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 4. Data on file: Guardant360 Brand Tracker, 2023. Guardant Health, Inc. Redwood City, CA.